Oxford’s Nucleome Therapeutics welcomes new CEO

Nucleome Therapeutics, an Oxford biotech using 3D genomics to discover medicines for complex diseases, has appointed Dr Mark Bodmer as CEO.

Mark joins from Evelo Biosciences, where since 2016 he’s served as chief scientific officer and president of R&D.

Previously, Mark held senior pharmaceutical and biotech roles including VP of New Medicines Therapeutics at UCB S.A, senior vice president of immunoinflammation at GSK, and CEO of Hexagen, Lorantis and Biotica.

He’s also served on the board of directors of the BioIndustry Association, and holds a PhD in genetics from the University of Cambridge.

“Nucleome has built a revolutionary technology platform which moves the field of genetics in medicine from its one-dimensional linear code to the interactions within its three-dimensional structure,” said Mark.

“This allows us to determine the regulatory wiring of gene function in health and disease in unprecedented detail.

“Nucleome’s uniquely powerful technology fills a critical gap in the application of genetics to drug discovery and healthcare.

“It’s a privilege to be given the opportunity to lead this ground-breaking company into its next phase of growth.”

Dr Russell Greig, non-executive chair of Nucleome, added: “Our pioneering science and technology are the innovative foundation for the future of Nucleome.

“In addition to Mark’s R&D background resulting in many marketed medicines, he has broad experience in company-building, business development, financing and M&A.

“His unusual combination of R&D and commercial expertise in driving great science towards patient benefits will be crucial in delivering Nucleome’s continued development.”